Optimism after much pessimism: What next?

Current Opinion in Immunology

Volumn 11, Issue 5, 1999, Pages 589-591

  Milstein, C ^a   Waldmann, H ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

CANCER; CANCER IMMUNOTHERAPY; DRUG TOXICITY; HUMAN; NOTE;

EID: 0032825454     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)00014-X     Document Type: Note

References (22)

1. G Kohler C Milstein Continuous cultures of fused cells secreting antibody of predifined specificity Nature 256 1975 495 497
2. G Galfre SC Howe C Milstein GW Butcher JC Howard Antibodies to major histocompatibility antigens produced by hybrid cell lines Nature 266 1977 550 552
3. AF Williams G Galfre C Milstein Analysis of cell surfaces by xenogenic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes Cell 12 1977 663 673
4. RA Miller DG Maloney R Warnke R Levy Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody N Engl J Med 306 1982 517 522
5. G Hale MR Clark R Marcus G Winter MJS Dyer JM Phillips L Riechmann H Waldmann Remission induction in non-hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H Lancet 8625 1988 1394 1399
6. A Durandy N Brousse F Rozenberg G De Saint-Basile AM Fischer A Fischer Control of human B cell tumor growth in severe combined immunodeficiency mice by monoclonal anti-B cell antibodies J Clin Invest 90 1992 945 952
7. GA Leget MS Czuczman Use of rituximab, the new FDA-approved antibody Curr Opin Oncol 10 1998 548 551
8. A Osterborg MJ Dyer D Bunjes GA Pangalis Y Bastion D Catovsky H Mellstedt Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia J Clin Oncol 15 1997 1567 1574
9. G Riethmuller E Holz G Schlimok W Schmiegel R Raab K Hoffke R Gruber I Funke H Pichlmaier H Hirche Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial J Clin Oncol 16 1998 1788 1794
10. R Dyall LV Vasovic RA Clynes ZJ Nikolic Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor Eur J Immunol 29 1999 30 37
11. JA Drebin VC Link MI Greene Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo Oncogene 2 1988 387 394
12. JA Drebin VC Link RA Weinberg MI Greene Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen Proc Natl Acad Sci USA 83 1986 9129 9133
13. MA Ghetie EM Podar A Ilgen BE Gordon JW Uhr ES Vitetta Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells Proc Natl Acad Sci USA 94 1997 7509 7514
14. OW Press JF Eary FR Appelbaum PJ Martin CC Badger WB Nelp S Glenn G Butchko D Fisher B Porter Radiolabelled antibody therapy of B-cell lymphoma with autologous marrow support N Eng J Med 329 1993 1219 1224
15. S Nicholson CS Gooden V Hird A Maraveyas P Mason HE Lambert CF Meares AA Epenetos Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis Oncol Rep 5 1998 223 226
16. PT Jones PH Dear J Foote MS Neuberger G Winter Replacing the complementarity-determining regions in a human antibody with those from a mouse Nature 321 1986 522 525
17. G Winter AD Griffiths RE Hawkins HR Hoogenboom Making antibodies by phage display technology Annu Rev Immunol 12 1994 433 455
18. M Bruggemann MS Neuberger Strategies for expressing human antibody repertoires in transgenic mice Immunol Today 17 1996 391 397
19. LK Gilliland LA Walsh MR Frewin MP Wise M Tone G Hale H Waldmann Elimination of the immunogenicity of therapeutic antibodies J Immunol 162 1999 3663 3671
20. LR Coney PT Daniel D Sanborn J Dhein KM Debatin PH Krammer VR Zurawski Jr. Apoptotic cell death induced by a mouse-human anti-APO-1 chimeric antibody leads to tumor regression Int J Cancer 58 1994 562 567
21. JC Howard GW Butcher G Galfre C Milstein CP Milstein Monoclonal antibodies as tools to analyse the serological and genetic complexities of major transplantation antigens Immunol Rev 47 1979 139 174
22. JA Drebin VC Link MI Greene Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo Oncogene 2 1988 273 277